L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML (NCT06788756)

🧪 Interventions in This Study

• Placebo in combination with Cytarabine Injection (DRUG)
• Liposomal Annamycin Injection in combination with Cytarabine Injection (DRUG)
• Liposomal Annamycin Injection in combination with Cytarabine Injection (DRUG)
• Liposomal Annamycin for Injection in combination with Cytarabine Injection. (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (28 Sites)

Showing the first 25 of 28 sites.

• University of Alabama Birmingham — Birmingham, Alabama
• Bioresearch Partners — Miami, Florida
• Augusta University - Georgia Cancer Center — Augusta, Georgia
• University of Nebraska Medical Center — Omaha, Nebraska
• Atlantic Health — Morristown, New Jersey
• University Hospitals Cleveland Medical Center — Cleveland, Ohio
• University of Pennsylvania — Philadelphia, Pennsylvania
• University of Rhode Island — Providence, Rhode Island
• Fakultní nemocnice Hradec Králové — Hradec Králové,
• GEORGIA: LLC ARENSIA Exploratory Medicine — Tbilisi,
• Caucasus Medical Center — Tbilisi,
• RCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia — Bologna,
• AOU Careggi — Florence,
• AUSL della Romagna - Santa Maria delle Croci - Ravenna — Ravenna,
• Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart — Roma,
• LSMU Kauno klinikos — Kaunas,
• Szpital Kliniczny MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie Oddział Kliniczny Hematologii i Chorób Wewnętrznych z Ośrodkiem Transplantacji Szpiku — Olsztyn,
• Oddział Hematologii i Transplantacji Szpiku, Uniwersytecki Szpital Kliniczny w Poznaniu — Poznan,
• Uniwersytecki Szpital Kliniczny Klinika Hematologii i Transplantologii (Szczecin) — Szczecin,
• Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu, Oddział Hematologii — Torun,
• Instytut Hematologii i Transfuzjologii, Klinika Hematologii — Warsaw,
• ARENSIA research clinic at the Oncology Institute "Prof. Dr. Ion Chiricuţă" — Cluj-Napoca,
• Institut Català d'Oncología (ICO) - Hospital Germans Trias i Pujol — Barcelona, Badalona
• Hospital Universitario Central de Asturias (HUCA) — Oviedo, Principality of Asturias
• Hospital MD Anderson Cancer Center Madrid — Madrid,

📞 Contact the Study Coordinator

Phone: (202) 760-1378

Email: pwaymack@moleculin.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Acute Myeloid Leukaemia (AML)

• A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax — Boston, Massachusetts
• A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies — Iowa City, Iowa

Explore by condition: All Acute Myeloid Leukaemia (AML) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.